口服 Tecovirimat 治疗新生儿猴痘一例
本文报告美国南部一名10日龄新生儿,表现为发热和全身丘疹脓疱疹,因皮疹特征及与母亲皮疹相似而早期怀疑猴痘感染。入院第3天开始口服 Tecovirimat,后经聚合酶链反应确诊猴痘;患儿耐受良好,预后良好,无感染后遗留影响。
要点
- 新生儿猴痘可表现为发热和全身丘疹脓疱疹,皮疹特征及与照料者皮疹相似有助于早期怀疑。
- 口服 Tecovirimat 在入院第3天启用,患儿耐受良好,预后良好且无遗留影响。
- 新生儿猴痘的临床表现、病程及抗病毒药物副作用在文献中报道较少。
核心结论
- 该10日龄新生儿猴痘患儿口服 Tecovirimat 耐受良好,预后良好,无感染后遗留影响。
研究设计与样本
- 本文为单例病例报告,对象为美国南部一名10日龄新生儿。
主要发现
- 患儿表现为发热和全身丘疹脓疱疹,因皮疹特征及与母亲先前皮疹相似而早期怀疑猴痘感染。
- 入院第3天开始口服 Tecovirimat,后经聚合酶链反应分析确诊猴痘。
- 患儿耐受口服 Tecovirimat 良好,预后良好,无感染后遗留影响。
临床怎么用
- 新生儿出现发热和全身丘疹脓疱疹时,应结合皮疹特征及与照料者皮疹的相似性早期考虑猴痘感染。
- 对疑似新生儿猴痘,可考虑口服 Tecovirimat 治疗,但需注意该年龄组药物副作用数据有限。
局限性
- 本文为单例病例报告,新生儿猴痘的临床表现、病程及抗病毒药物副作用信息有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Since the Monkeypox virus outbreak erupted in May 2022, infection has been reported across all ages. Few cases exist in the medical literature about Monkeypox infection in neonates, and little is known about its clinical manifestations, disease course, or side effects of available antiviral agents in this age group. In this report, we describe the case of a 10-day-old neonate from the southern United States who presented with fevers and generalized papulopustular rash. She was treated empirically as a febrile neonate but mpox infection was suspected early because of the characteristic exanthem and its similarity to her mother's rash that she had developed a few days before the patient's presentation. Oral tecovirimat was initiated on the third day of admission and mpox was later confirmed by polymerase chain reaction analysis. The patient tolerated oral tecovirimat well and experienced a favorable outcome without lasting effects of infection.
引用
- Castejon-Ramirez S, Pennington J, Beene H, et al. A Case of Neonatal Monkeypox Treated With Oral Tecovirimat. Pediatrics. 2024. PMID: 38148743. doi:10.1542/peds.2023-061198
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。